Ind-Swift Laboratories

INDSWFTLAB · NSE

— · —

₹413.1

Closing price — 29 Sept 2026

Market cap ₹2,441 Cr · EPS ₹7.01

Valuation

Blended fair value using DCF and peer comparison methods.

See if Ind-Swift Laboratories is undervalued

Unlock intrinsic value for 4,800+ Indian stocks — free.

Moderately cyclical company. Peer comparison weighted higher than DCF.

The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.

Peer comparison

How this company stacks up against sector peers on valuation and quality metrics.

Healthcare · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Ind-Swift Laboratories INDSWFTLAB · you	₹2,390 Cr	57.7×	1.7×	55.3×	3.0%	6.5%	-19.0%
Sector median	—	43.0×	6.6×	21.3×	12.6%	3.2%	10.2%
Dr. Agarwal's Health Care Limited AGARWALEYE	₹16,045 Cr	349.0×	—	—	—	0.0%	—
Alembic Pharmaceuticals Limited APLLTD	₹15,334 Cr	24.2×	2.9×	15.6×	11.9%	9.2%	9.1%
Park Medi World Limited PARKHOSPS	₹12,549 Cr	40.9×	6.0×	27.2×	12.8%	15.4%	10.2%
Akums Drugs and Pharmaceuticals Limited AKUMS	₹12,161 Cr	45.1×	3.5×	20.9×	7.7%	5.9%	6.0%
Thyrocare Technologies Limited THYROCARE	₹9,929 Cr	60.9×	20.7×	—	34.0%	0.2%	—
Jupiter Life Line Hospitals Limited JLHL	₹9,880 Cr	53.4×	6.7×	29.1×	12.6%	12.9%	18.9%
Procter & Gamble Health Limited PGHL	₹9,850 Cr	27.6×	16.1×	—	58.5%	0.3%	—
Healthcare Global Enterprises Limited HCG	₹8,780 Cr	638.1×	6.6×	21.3×	1.0%	0.5%	14.5%

Peer comparison verdict

Ind-Swift trades at a premium to sector peers on P/E (58.9× vs median 43.0×). The market is pricing in higher growth — worth verifying whether recent revenue trends support that expectation.

Business quality

Valuation

P/E ratio

58.9×

P/B ratio

—

EV/EBITDA

—

Price/Sales

—

Returns

ROE

3.0%

ROCE

0.2%

ROA

—

Growth

Revenue CAGR (3yr)

-19.0%

EPS CAGR (3yr)

-4.5%

Efficiency

Asset turnover

—

FCF yield

-6.2%

Dividend yield

—

Liquidity & Solvency

Debt / Equity

0.01×

Debt / EBITDA

—

Interest coverage

2.5×

Current ratio

3.80×

Quick ratio

—

Financial health

Piotroski F-Score, Altman Z-Score, and key solvency ratios.

Financial health data is not yet available for this company.

Full financial data

Charts and annual statements for income, balance sheet and cash flow.

Income trend

Revenue, profit and margin trends over time.

Revenue

Net profit

Operating margin

Net margin

Revenue

₹641 Cr

Net profit

₹41 Cr

Operating margin

—

Net margin

6.5%

Revenue and net profit in ₹ Crores (left axis). Margins % on right axis.

Cash flow

Where cash comes from and where it goes.

Operating CFInvesting CFFinancing CFFree cash flow

Operating CF — Cash earned from running the business. The core engine of financial health.

Investing CF — Cash spent on assets and equipment. Negative is normal — it means the company is investing in growth.

Financing CF — Cash from borrowing or repaying loans and dividends. Negative means debt is being repaid.

Free cash flow — Operating CF minus capex. Cash left after keeping the business running. Positive and growing is ideal.

Operating CF

-₹64.39 Cr

Investing CF

₹0 Cr

Financing CF

₹0 Cr

Free cash flow

-₹152.11 Cr

Balance sheet

Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.

How the company is funded — equity is owners' money, debt is long-term borrowing, current liabilities are short-term obligations.

Equity

Debt

Current liabilities

Total assets

—

Total debt

₹18 Cr

Equity

₹1,384 Cr

Debt / Equity

0.01×

Numbers are illustrative — order-of-magnitude correct. For precise figures, refer to the company's annual report on BSE/NSE.

Shareholding pattern

Who owns this company and how that has changed.

What shareholding tells you: When promoters (founders/controlling shareholders) increase their stake, it usually signals confidence in the business. Rising FII (foreign funds) interest means international money is moving in. High promoter pledge is a risk — pledged shares can be force-sold if the stock price falls sharply.

Latest quarter

Promoter

42.9%

-0.1 pp QoQ

FII

10.7%

-3.2 pp QoQ

DII

0.2%

+0.2 pp QoQ

Retail

46.2%

Trend over time (%)

Quarterly data

Category	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Change (YoY)
Promoter	42.0%	42.0%	42.0%	42.0%	42.0%	42.0%	40.9%	40.9%	39.5%	39.5%	43.0%	42.9%	+2.0 ppYoY
FII (Foreign)	0.2%	0.3%	0.3%	1.3%	0.7%	0.5%	3.1%	4.3%	14.8%	14.3%	13.9%	10.7%	+6.4 ppYoY
DII (Domestic)	19.5%	18.7%	8.0%	0.9%	0.9%	0.9%	0.9%	0.9%	0.7%	0.7%	0.0%	0.2%	-0.7 ppYoY
Retail	38.3%	39.0%	49.7%	55.8%	56.4%	56.6%	55.1%	53.9%	45.0%	45.5%	43.1%	46.2%	-7.7 ppYoY

Signals from the trend

📈

PromoterUp 0.9pp — insiders are adding to their stake

📈

FIINet buyers (+10.5pp) — foreign institutional interest is growing

📉

DIINet sellers (19.3pp) — domestic funds are reducing

Overall positive — promoter buying and FII buying suggest growing conviction in the business.

pp = percentage points. FII = Foreign Institutional Investors. DII = Domestic Institutional Investors (MFs, insurance). Data sourced from NSE/BSE filings. Verify on BSE/NSE before any investment decision.